New antiviral strategy using capsid-nuclease fusion proteins

Georges Natsoulis, Jef D. Boeke

Research output: Contribution to journalArticle

Abstract

Overexpression of dominant-negative mutants of various viral proteins can result in 'intracellular immunization' (refs 1, 2). Here we describe a new approach to interfering with viral replication in which a nuclease is fused to a capsid component so that the nuclease is encapsidated inside the virion where it can inactivate viral nucleic acid. We used Tyl, a yeast retrotransposon whose transposition closely parallels retroviral replication mechanisms and serves as an easily manipulated model for the retroviral infection process3. We constructed fusion genes consisting of the region encoding the N-terminal portion of the TYA/TYB open reading frames of retrotransposon Tyl and either of two different nuclease genes. Tyl-nuclease fusion proteins are targeted to Tyl virus-like particles, and are active in degrading nucleic acids. A Tyl-barnase fusion protein causes 98-99% reduction in the efficiency of Tyl transposition in vivo, presumably by degrading encapsidated Tyl RNA. This strategy, referred to as capsid- targeted viral inactivation, may be useful for interfering with the replication of retroviruses and other viruses.

Original languageEnglish (US)
Pages (from-to)632-635
Number of pages4
JournalNature
Volume352
Issue number6336
DOIs
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'New antiviral strategy using capsid-nuclease fusion proteins'. Together they form a unique fingerprint.

  • Cite this